Artikler med mandater om offentlig tilgang - Hope RugoLes mer
Ikke tilgjengelige noe sted: 19
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo …
PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ...
The Lancet 390 (10105), 1833-1842, 2017
Mandater: US National Institutes of Health
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results …
P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ...
The lancet oncology 21 (1), 44-59, 2020
Mandater: US Department of Defense, US National Institutes of Health
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised …
S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ...
The lancet oncology 19 (4), 497-509, 2018
Mandater: US National Institutes of Health
Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology
J Crawford, PS Becker, JO Armitage, DW Blayney, J Chavez, P Curtin, ...
Journal of the National Comprehensive Cancer Network 15 (12), 1520-1541, 2017
Mandater: US National Institutes of Health
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
Mandater: Susan G. Komen
Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors
EE Niemasik, J Letourneau, D Dohan, A Katz, M Melisko, H Rugo, ...
Journal of Cancer Survivorship 6, 324-332, 2012
Mandater: US National Institutes of Health
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival
ME Melisko, DH Moore, PK Sneed, J De Franco, HS Rugo
Journal of neuro-oncology 88, 359-365, 2008
Mandater: US National Institutes of Health
Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer
JS Lee, ME Melisko, MJM Magbanua, AT Kablanian, JH Scott, HS Rugo, ...
Breast cancer research and treatment 154, 339-349, 2015
Mandater: US National Institutes of Health
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
AJ Chien, A Cockerill, C Fancourt, E Schmidt, MM Moasser, HS Rugo, ...
Breast cancer research and treatment 155, 521-530, 2016
Mandater: US National Institutes of Health
The role of targeted therapy and biomarkers in breast cancer treatment
AT Stopeck, U Brown-Glaberman, HY Wong, BH Park, SE Barnato, ...
Clinical & experimental metastasis 29, 807-819, 2012
Mandater: US National Institutes of Health
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033: ATEMPT Trial)
KJ Ruddy, Y Zheng, N Tayob, J Hu, CT Dang, DA Yardley, SJ Isakoff, ...
Breast Cancer Research and Treatment 189 (1), 103-110, 2021
Mandater: Susan G. Komen
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA. 21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer
AE Lohmann, JAW Chapman, MJ Burnell, MN Levine, E Tsvetkova, ...
Breast Cancer Research and Treatment 150, 605-611, 2015
Mandater: US National Institutes of Health, Canadian Cancer Society, Ontario Institute …
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers
I Vaz-Luis, ME Hughes, A Cronin, HS Rugo, SB Edge, B Moy, ...
Breast cancer research and treatment 155, 569-578, 2016
Mandater: US National Institutes of Health, Fundação para a Ciência e a Tecnologia …
Impact of BMI in patients with early hormone receptor–positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial
G Pfeiler, D Hlauschek, EL Mayer, C Deutschmann, S Kacerovsky-Strobl, ...
Journal of Clinical Oncology 41 (33), 5118-5130, 2023
Mandater: Cancer Research UK
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer
AJ Chien, E Duralde, R Hwang, K Tsung, CN Kao, HS Rugo, ME Melisko, ...
Breast cancer research and treatment 153, 173-181, 2015
Mandater: US National Institutes of Health
Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates
J Belkora, HS Rugo, DH Moore, D Hutton, L Esserman
The lancet oncology 9 (7), 602-603, 2008
Mandater: US National Institutes of Health
Risk-based screening for cancer in patients with dermatomyositis: toward a more individualized approach
H Vaughan, HS Rugo, A Haemel
JAMA dermatology 158 (3), 244-247, 2022
Mandater: US National Institutes of Health
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study
LA Huppert, Z Walker, M Li, MO Kim, J Callan, D Brandman, M Majure, ...
Breast Cancer Research and Treatment 197 (1), 137-148, 2023
Mandater: US National Institutes of Health
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer—Reply
ME Melisko, J Hwang, HS Rugo
JAMA oncology 3 (8), 1142-1142, 2017
Mandater: US National Institutes of Health, Susan G. Komen
Tilgjengelige et eller annet sted: 176
Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer
J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ...
New England Journal of Medicine 366 (6), 520-529, 2012
Mandater: US National Institutes of Health
Informasjon om publisering og finansiering fastsettes automatisk av et datamaskinprogram